Thioester Cationic Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids for nucleic acid delivery face challenges in achieving targeted and efficient delivery to various cell types and tissues with reduced toxicity, while maintaining stability and efficient release of encapsulated materials.
Innovation Solution
Development of novel cationic lipids with specific structural formulas (I-VI) that enhance transfection efficiency, cellular uptake, and endosomal disruption, formulated into liposomal compositions for targeted delivery of mRNA encoding proteins or peptides for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cationic lipids are used for nucleic acid delivery, then transfection efficiency is achieved, but toxicity increases and targeted delivery is limited
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the headgroup composition (combining quaternary ammonium and tertiary amine groups), chain length, and saturation levels. These parameter changes optimize the balance between transfection efficiency and toxicity, creating lipids that are effective at delivering nucleic acids while reducing harmful effects on cells.
Solution Approach 2:
The invention creates composite lipid structures that integrate multiple functional components within a single lipid molecule. The cationic lipids combine different amino groups (quaternary and tertiary) with specific hydrocarbon chains, forming composite structures that simultaneously provide transfection capability, reduced toxicity, and improved stability.
2Quantity of substance
If current cationic lipids are used for nucleic acid delivery, then encapsulation is achieved, but stability and efficient release are compromised
Solution Approach 1:
The patent applies local quality by creating lipids with distinct functional regions: a cationic headgroup for nucleic acid binding and encapsulation, and specific hydrocarbon tail structures for membrane interaction and release. This local differentiation of properties within the lipid molecule enables simultaneous achievement of encapsulation capacity and controlled release stability.
3Productivity
If current cationic lipids are used for delivery, then cellular uptake is achieved, but targeted delivery to specific tissues is limited
Solution Approach 1:
The patent modifies physical and chemical parameters of the cationic lipids, including charge density, hydrophobicity, and molecular size, to enhance both cellular uptake efficiency and tissue targeting capability. These parameter optimizations allow the lipids to interact effectively with cell membranes while exhibiting preferential accumulation in specific tissues.
Data Source
AI summary
Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI).Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.